Copenhagen, 2017-10-12 22:43 CEST (GLOBE NEWSWIRE) --
Pursuant to section 29 of the Danish Securities Trading Act, ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) has received notification from Jupiter Asset Management Ltd., that Jupiter Asset Management Ltd. has reduced its ownership in ALK to below 5% of the share capital.
The notifications from Jupiter Asset Management Ltd. are attached to this company release.
ALK-Abelló A/S
For further information please contact:
Investor Relations: Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525
About ALK
ALK is a research-driven global pharmaceutical company focusing on allergy prevention, diagnosis and treatment. ALK is a world leader in allergy immunotherapy — a treatment of the underlying cause of allergy. The company has approximately 2,300 employees, with subsidiaries, production facilities and distributors worldwide. ALK has entered into partnership agreements with Torii, Abbott, and Seqirus to commercialise sublingual allergy immunotherapy tablets in Japan, Russia, and South-East Asia, and Australia and New Zealand, respectively. The company is headquartered in Hørsholm, Denmark, and listed on Nasdaq Copenhagen. Find more information at www.alk.net.